Diagnosis and treatment of Marfan syndrome: An update

Heart

Volumn 100, Issue 17, 2014, Pages 1382-1391

  Radke, Robert M ^a   Baumgartner, Helmut ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOSARTAN;

AORTA DISEASE; AORTA DISSECTION; AORTA RUPTURE; AORTIC ROOT SURGERY; ARTERY DILATATION; ARTERY DISEASE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; ENDOVASCULAR SURGERY; FOLLOW UP; GENETIC ANALYSIS; HUMAN; IMAGE RECONSTRUCTION; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MARFAN SYNDROME; MATERNAL CARE; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

CONGENITAL HEART DISEASE;

ANEURYSM, DISSECTING; AORTIC ANEURYSM; AORTIC RUPTURE; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MARFAN SYNDROME; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84905443211     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304709     Document Type: Article

References (20)

1. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-41. Landmark study on the effect of prophylactic β-blocker therapy on progression of aortic dilatation in MFS.
2. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 1999;340:1307-13. Landmark study on the value of prophylactic aortic root surgery in MFS. (Pubitemid 29196592)
3. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476-85. The latest nosology for the Marfan syndrome from 2010.
4. Yetman AT, Roosevelt GE, Veit N, et al. Distal aortic and peripheral arterial aneurysms in patients with Marfan syndrome. J Am Coll Cardiol 2011;58:2544-5.
5. Gaertner S, Alembik Y, Cordeanu EM, et al. Should we systematically screen for peripheral arterial aneurysms in all patients with Marfan syndrome? Int J Cardiol 2014;172:e94-5.
6. Sheikhzadeh S, Kusch ML, Rybczynski M, et al. A simple clinical model to estimate the probability of Marfan syndrome. QJM 2012;105:527-35.
7. Roman MJ, Devereux RB, Kramer-Fox R, et al. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989;64:507-12. This study provides one of the most commonly used equations for the calculation of z-scores of the aortic root in adults. (Pubitemid 19214582)
8. Radonic T, de Witte P, Groenink M, et al. Critical appraisal of the revised Ghent criteria for diagnosis of Marfan syndrome. Clin Genet 2011;80:346-53.
9. Devereux RB, de Simone G, Arnett DK, et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol 2012;110:1189-94. Provides two new equations for the calculation of z-scores of the aortic root. A high number of subjects were studied.
10. Sheikhzadeh S, Kade C, Keyser B, et al. Analysis of phenotype and genotype information for the diagnosis of Marfan syndrome. Clin Genet 2012;82:240-7.
11. Stheneur C, Collod-Beroud G, Faivre L, et al. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet 2009;17:1121-8.
12. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-57.
13. Thakur V, Rankin KN, Hartling L, et al. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome. Cardiol Young 2013;23:568-81. Comprehensive review of the pharmacological management of MFS. Does not include the results of the first large study on losartan.
14. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21. Landmark study on the effect of losartan in a mouse model of MFS. This study inspired a large number of ongoing clinical trials in humans.
15. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan' s syndrome. N Engl J Med 2008;358:2787-95. (Pubitemid 351930853)
16. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013;34:3491-500. Encouraging results from the first prospective, randomised, open-label, multicentre trial on the effect of losartan on aortic dilatation in adult MFS patients.
17. Benedetto U, Melina G, Takkenberg JJ, et al. Surgical management of aortic root disease in Marfan syndrome: a systematic review and meta-analysis. Heart 2011;97:955-8.
18. Pacini D, Parolari A, Berretta P, et al. Endovascular treatment for type B dissection in Marfan syndrome: is it worthwhile? Ann Thorac Surg 2013;95:737-49.
19. Donnelly RT, Pinto NM, Kocolas I, et al. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. J Am Coll Cardiol 2012;60:224-9.
20. Franken R, den Hartog AW, de Waard V, et al. Circulating transforming growth factor-beta as a prognostic biomarker in Marfan syndrome. Int J Cardiol 2013;168:2441-6.